The current prospects for neutrophil transfusions for the treatment of granulocytopenic infected patients.
Infection continues to be a major cause of morbidity and mortality in patients undergoing aggressive chemotherapy and hematopoietic stem cell transplantation. The provision of normal neutrophils to such patients is a logical therapeutic approach, the success of which will likely be dependent on the dose of neutrophils provided. Stimulation of normal leukapheresis donors with G-CSF or dexamethasone causes marked neutrophilia and results in the collection of greatly increased numbers of neutrophils. Transfusion recipients, on average, exhibit large posttransfusion neutrophil increments that are sustained for 24 hours. These cells are capable of migrating to extravascular sites. Although the preliminary clinical impressions are encouraging, the clinical efficacy of transfusing large numbers of neutrophils will have to be determined by randomized controlled clinical trials.